Vai trò của Protein tiền thân Amyloid (APP) và các dẫn xuất của nó trong sinh học và xác định số phận tế bào của tế bào gốc thần kinh

Müller UC, Deller T, Korte M (2017) Not just amyloid: physiological functions of the amyloid precursor protein family. Nat Rev Neurosci 18(5):281–298 Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K (1985) Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A 82(12):4245–4249 Dawkins E, Small DH (2014) Insights into the physiological function of the β-amyloid precursor protein: beyond Alzheimer’s disease. J Neurochem 129(5):756–769 Van der Kant R, Goldstein LS (2015) Cellular functions of the amyloid precursor protein from development to dementia. Dev Cell 32(4):502–515 Kirazov E, Kirazov L, Bigl V, Schliebs R (2001) Oncogenetic changes in protein level of amyloid precursor protein (APP) in growth cones and synaptosomes from rat brain and prenatal expression pattern of APP mRNA isoforms in developing rat embryo. Int J Dev Neurosci 19(3):287–296 Tyan SH, Shih AY, Walsh JJ, Maruyama H, Sarsoza F, Ku L, Eggert S, Hof PR et al (2012) Amyloid precursor protein (APP) regulates synaptic structure and function. Mol Cell Neurosci 51(1–2):43–52 Wang Z, Wang B, Yang L, Guo Q, Aithmitti N, Songyang Z, Zheng H (2009) Presynaptic and postsynaptic interaction of the amyloid precursor protein promotes peripheral and central synaptogenesis. J Neurosci 29(35):10788–10801 Milward EA, Papadopoulos R, Fuller SJ, Moir RD, Small D, Beyreuther K, Masters CL (1992) The amyloid protein precursor of Alzheimer’s disease is a mediator of the effects of nerve growth factor on neurite outgrowth. Neuron 9(1):129–137 Young-Pearse TL, Bai J, Chang R, Zheng JB, LoTurco JJ, Selkoe DJ (2007) A critical function for beta-amyloid precursor protein in neuronal migration revealed by in utero RNA interference. J Neurosci 27(52):14459–14469 Bolós M, Hu Y, Young KM, Foa L, Small DH (2014) Neurogenin 2 mediates amyloid-β precursor protein-stimulated neurogenesis. J Biol Chem 289(45):31253–31261 Hu Y, Hung AC, Cui H, Dawkins E, Bolós M, Foa L, Young KM, Small DH (2013) Role of cystatin C in amyloid precursor protein-induced proliferation of neural stem/progenitor cells. J Biol Chem 288(26):18853–18862 Zhou L, Brouwers N, Benilova I, Vandersteen A, Mercken M, Van Laere K, Van Damme P, Demedts D et al (2011) Amyloid precursor protein mutation E682K at the alternative β-secretase cleavage β’-site increases Aβ generation. EMBO Mol Med 3(5):291–302 López-Toledano MA, Shelanski ML (2004) Neurogenic effect of beta-amyloid peptide in the development of neural stem cells. J Neurosci 24(23):5439–5444 López-Toledano MA, Shelanski ML (2007) Increased neurogenesis in young transgenic mice overexpressing human APP (Sw, Ind). J Alzheimers Dis 12(3):229–240 Jin K, Galvan V, Xie L, Mao XO, Gorostiza OF, Bredesen DE, Greenberg DA (2004) Enhanced neurogenesis in Alzheimer’s disease transgenic (PDGF-APPSw, Ind) mice. Proc Natl Acad Sci U S A 101(36):13363–13367 Caillé I, Allinquant B, Dupont E, Bouillot C, Langer A, Müller U, Prochiantz A (2004) Soluble form of amyloid precursor protein regulates proliferation of progenitors in the adult subventricular zone. Development 131(9):2173–2181 Wang X, Huang T, Bu G, Xu H (2014) Dysregulation of protein trafficking in neurodegeneration. Mol Neurodegener 9:31 Revilla A, González C, Iriondo A, Fernández B, Prieto C, Marín C, Liste I (2015) Current advances in the generation of human iPS cells: implications in cell-based regenerative medicine. J Tissue Eng Regen Med. https://doi.org/10.1002/term.2021 Martínez-Morales PL, Revilla A, Ocaña I, González C, Sainz P, McGuire D, Liste I (2013) Progress in stem cell therapy for major human neurological disorders. Stem Cell Rev 9(5):685–699 Lindvall O, Kokaia Z (2010) Stem cells in human neurodegenerative disorders—time for clinical translation? J Clin Invest 120(1):29–40 González C, Bonilla S, Flores AI, Cano E, Liste I (2015) An update on human stem cell-based therapy in Parkinson’s disease. Curr Stem Cell Res Ther 11(7):561–568 Porayette P, Gallego MJ, Kaltcheva MM, Meethal SV, Atwood CS (2007) Amyloid-beta precursor protein expression and modulation in human embryonic stem cells: a novel role for human chorionic gonadotropin. Biochem Biophys Res Commun 364(3):522–527 Lee IS, Jung K, Kim IS, Park KI (2013) Amyloid-β oligomers regulate the properties of human neural stem cells through GSK-3β signaling. Exp Mol Med 45:e60 Yasuoka K, Hirata K, Kuraoka A, He JW, Kawabuchi M (2004) Expression of amyloid precursor protein-like molecule in astroglial cells of the subventricular zone and rostral migratory stream of the adult rat forebrain. J Anat 205(2):135–146 Nalivaeva NN, Turner AJ (2013) The amyloid precursor protein: a biochemical enigma in brain development, function and disease. FEBS Lett 587(13):2046–2054 Zheng H, Koo EH (2006) The amyloid precursor protein: beyond amyloid. Mol Neurodegener 1:5 Buoso E, Lanni C, Schettini G, Govoni S, Racchi M (2010) Beta-amyloid precursor protein metabolism: focus on the functions and degradation of its intracellular domain. Pharmacol Res 62(4):308–317 Willem M, Tahirovic S, Busche MA, Ovsepian SV, Chafai M, Kootar S, Hornburg D, Evans LD et al (2015) η-Secretase processing of APP inhibits neuronal activity in the hippocampus. Nature 526(7573):443–447 Grimm MO, Mett J, Stahlmann CP, Haupenthal VJ, Zimmer VC, Hartmann T (2013) Neprilysin and Aβ clearance: impact of the APP intracellular domain in NEP regulation and implications in Alzheimer’s disease. Front Aging Neurosci 5:98 Thinakaran G, Koo EH (2008) Amyloid precursor protein trafficking, processing, and function. J Biol Chem 283(44):29615–29619 Cao X, Südhof TC (2001) A transcriptionally [correction of transcriptively] active complex of APP with Fe65 and histone acetyltransferase Tip60. Science 293(5527):115–120 Sisodia SS, St George-Hyslop PH (2002) γ-Secretase, Notch, Abeta and Alzheimer’s disease: where do the presenilins fit in? Nat Rev Neurosci 3(4):281–290 Burnouf S, Gorsky MK, Dols J, Grönke S, Partridge L (2015) Aβ43 is neurotoxic and primes aggregation of Aβ40 in vivo. Acta Neuropathol 130(1):35–47 Sandebring A, Welander H, Winblad B, Graff C, Tjernberg LO (2013) The pathogenic Aβ43 is enriched in familial and sporadic Alzheimer disease. PLoS One 8(2):e55847 Keller L, Welander H, Chiang HH, Tjernberg LO, Nennesmo I, Wallin AK, Graff C (2010) The PSEN1 I143T mutation in a Swedish family with Alzheimer’s disease: Clinical report and quantification of Aβ in different brain regions. Eur J Hum Genet 18(11):1202–1208 Welander H, Frånberg J, Graff C, Sundström E, Winblad B, Tjernberg LO (2009) Abeta43 is more frequent than Abeta40 in amyloid plaque cores from Alzheimer disease brains. J Neurochem 110(2):697–706 Van Vickle GD, Esh CL, Koklohn TA, Patton RL, Kalback WM, Luehrs DC, Beach TG, Newel AJ et al (2008) Presenilin-1 280Glu→Ala mutation alters C-terminal APP processing yielding longer Aβ peptides: implications for Alzheimer’s disease. Mol Med 14(3–4):184–194 Miravalle L, Calero M, Takao M, Roher AE, Ghetti B, Vidal R (2005) Amino-terminally truncated Abeta peptide species are the main component of cotton wool. Biochemistry 44(32):10810–10821 Selkoe DJ, Hardy J (2016) The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol Med 8(6):595–608 McGowan E, Pickford F, Kim J, Onstead L, Eriksen J, Yu C, Skipper L, Murphy MP et al (2005) Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron 47(2):191–199 Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 297(5580):353–356 Haass C, Kaether C, Thinakaran G, Sisodia S (2012) Trafficking and proteolytic processing of APP. Cold Spring Harb Perspect Med 2(5):a006270 Ehehalt R, Keller P, Haass C, Thiele C, Simons K (2003) Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J Cell Biol 160(1):113–123 Zhang Z, Song M, Liu X, Su Kang S, Duong DM, Seyfried NT, Cao X, Cheng L et al (2015) Delta-secretase cleaves amyloid precursor protein and regulates the pathogenesis in Alzheimer’s disease. Nat Commun 6:8762 Jefferson T, Čaušević M, auf dem keller U, Schilling O, Isbert S, Geyer R, Maier W, Tschickardt S et al (2011) Metalloprotease meprin beta generates nontoxic N-terminal amyloid precursor protein fragments in vivo. J Biol Chem 286(31):27741–27750 Norstrom E (2017) Metabolic processing of the amyloid precursor protein—new pieces of the Alzheimer’s puzzle. Discov Med 23(127):269–276 Porayette P, Gallego MJ, Kaltcheva MM, Bowen RL, Vadakkadath Meethal S, Atwood CS (2009) Differential processing of amyloid-beta precursor protein directs human embryonic stem cell proliferation and differentiation into neuronal precursor cells. J Biol Chem 284(35):23806–23817 Freude KK, Penjwini M, Davis JL, LaFerla FM, Blurton-Jones M (2011) Soluble amyloid precursor protein induces rapid neural differentiation of human embryonic stem cells. J Biol Chem 286(27):24264–24274 Chen Y, Tang BL (2006) The amyloid precursor protein and postnatal neurogenesis/neuroregeneration. Biochem Biophys Res Commun 341(1):1–5 Demars MP, Hollands C, Zhao Kda T, Lazarov O (2013) Soluble amyloid precursor protein-α rescues age-linked decline in neural progenitor cell proliferation. Neurobiol Aging 34(10):2431–2440 Ohsawa I, Takamura C, Morimoto T, Ishiguro M, Kohsaka S (1999) Amino-terminal region of secreted form of amyloid precursor protein stimulates proliferation of neural stem cells. Eur J Neurosci 11(6):1907–1913 Demars MP, Bartholomew A, Strakova Z, Lazarov O (2011) Soluble amyloid precursor protein: a novel proliferation factor of adult progenitor cells of ectodermal and mesodermal origin. Stem Cell Res Ther 2(4):36 Trazzi S, Mitrugno VM, Valli E, Fuchs C, Rizzi S, Guidi S, Perini G, Bartesaghi R et al (2011) APP-dependent up-regulation of Ptch1 underlies proliferation impairment of neural precursors in Down syndrome. Hum Mol Genet 20(8):1560–1573 Nicolas M, Hassan BA (2014) Amyloid precursor protein and neural development. Development 141(13):2543–2548 Kwak YD, Brannen CL, Qu T, Kim HM, Dong X, Soba P, Majumdar A, Kaplan A et al (2006) Amyloid precursor protein regulates differentiation of human neural stem cells. Stem Cells Dev 15(3):381–389 Kwak YD, Marutle A, Dantuma E, Merchant S, Bushnev S, Sugaya K (2011) Involvement of notch signaling pathway in amyloid precursor protein induced glial differentiation. Eur J Pharmacol 650(1):18–27 Kwak YD, Dantuma E, Merchant S, Bushnev S, Sugaya K (2010) Amyloid-β precursor protein induces glial differentiation of neural progenitor cells by activation of the IL-6/gp130 signaling pathway. Neurotox Res 18(3–4):328–338 Kwak YD, Hendrix BJ, Sugaya K (2014) Secreted type of amyloid precursor protein induces glial differentiation by stimulating the BMP/Smad signaling pathway. Biochem Biophys Res Commun 447(3):394–399 Baratchi S, Evans J, Tate WP, Abraham WC, Connor B (2012) Secreted amyloid precursor proteins promote proliferation and glial differentiation of adult hippocampal neural progenitor cells. Hippocampus 22(7):1517–1527 Chasseigneaux S, Allinquant B (2012) Functions of Aβ, sAPPα and sAPPβ: similarities and differences. J Neurochem 120(1):99–108 Jiang J, Wang Y, Hou L, Fan L, Wang Q, Xu Z, Sun Q, Liu H (2013) Distinct roles of sAPP-α and sAPP-β in regulating U251 cell differentiation. Curr Alzheimer Res 10(7):706–713 Fonseca MB, Solá S, Xavier JM, Dionísio PA, Rodrigues CM (2013) Amyloid β peptides promote autophagy-dependent differentiation of mouse neural stem cells: Aβ-mediated neural differentiation. Mol Neurobiol 48(3):829–840 Chen Y, Dong C (2009) Abeta40 promotes neuronal cell fate in neural progenitor cells. Cell Death Differ 16(3):386–394 Beckett C, Nalivaeva NN, Belyaev ND, Turner AJ (2012) Nuclear signalling by membrane protein intracellular domains: the AICD enigma. Cell Signal 24(2):402 Zhang YW, Wang R, Liu Q, Zhang H, Liao FF, Xu H (2007) Presenilin/γ-secretase-dependent processing of β-amyloid precursor protein regulates EGF receptor expression. Proc Natl Acad Sci U S A 104(25):10613–10618 Ayuso-Sacido A, Moliterno JA, Kratovac S, Kapoor GS, O’Rourke DM, Holland EC, García-Verdugo JM, Roy NS et al (2010) Activated EGFR signaling increases proliferation, survival, and migration and blocks neuronal differentiation in post-natal neural stem cells. J Neuro-Oncol 97(3):323–337 Ghosal K, Stathopoulos A, Pimplikar SW (2010) APP intracellular domain impairs adult neurogenesis in transgenic mice by inducing neuroinflammation. PLoS One 5(7):e11866 Ma QH, Bagnard D, Xiao ZC, Dawe GS (2008) A TAG on to the neurogenic functions of APP. Cell Adhes Migr 2(1):2–8 Trazzi S, Fuchs C, Valli E, Perini G, Bartesaghi R, Ciani E (2013) The amyloid precursor protein (APP) triplicated gene impairs neuronal precursor differentiation and neurite development through two different domains in the Ts65Dn mouse model for Down syndrome. J Biol Chem 288(29):20817–20829 Trazzi S, Fuchs C, De Franceschi M, Mitrugno VM, Bartesaghi R, Ciani E (2014) APP-dependent alteration of GSK3β activity impairs neurogenesis in the Ts65Dn mouse model of Down syndrome. Neurobiol Dis 67:24–36 Ghosal K, Vogt DL, Liang M, Shen Y, Lamb BT, Pimplikar SW (2009) Alzheimer’s disease-like pathological features in transgenic mice expressing the APP intracellular domain. Proc Natl Acad Sci U S A 106(43):18367–18372 Shu R, Wong W, Ma QH, Yang ZZ, Zhu H, Liu FJ, Wang P, Ma J et al (2015) APP intracellular domain acts as a transcriptional regulator of miR-663 suppressing neuronal differentiation. Cell Death Dis 6:e1651 Zhou ZD, Chan CH, Ma QH, Xu XH, Xiao ZC, Tan EK (2011) The roles of amyloid precursor protein (APP) in neurogenesis: Implications to pathogenesis and therapy of Alzheimer disease. Cell Adhes Migr 5(4):280–292 Lu DC, Soriano S, Bredesen DE, Koo EH (2003) Caspase cleavage of the amyloid precursor protein modulates amyloid beta-protein toxicity. J Neurochem 87(3):733–741 Ohkawara T, Nagase H, Koh CS, Nakayama K (2011) The amyloid precursor protein intracellular domain alters gene expression and induces neuron-specific apoptosis. Gene 475(1):1–9 Lazarov O, Demars MP (2012) All in the family: how the APPs regulate neurogenesis. Front Neurosci 6:81 Sindi S, Mangialasche F, Kivipelto M (2015) Advances in the prevention of Alzheimer’s disease. F1000prime Rep 7:50 Baumgart M, Snyder HM, Carrillo MC, Fazio S, Kim H, Johns H (2015) Summary of the evidence on modifiable risk factor for cognitive decline and dementia: a population-based perspective. Alzheimers Dement 11(6):718–726 Burns A, Byrne EJ, Maurer K (2002) Alzheimer’s disease. Lancet 360(9327):163–165 Barnes DE, Yaffe K (2011) The projected effect of risk factor reduction on Alzheimer’s disease prevalence. Lancet Neurol 10(9):819–828 Daviglus ML, Plassman BL, Pirzada A, Bell CC, Bowen PE, Burke JR, Connolly ES, Dunbar-Jacob JM et al (2011) Risk factors and preventive interventions for Alzheimer disease: state of the science. Arch Neurol 68(9):1185–1190 Millan MJ (2014) The epigenetic dimension of Alzheimer’s disease: causal, consequence, or curiosity? Dialogues Clin Neurosci 16(3):373–393 Setó-Salvia N, Clarimón J (2010) Genetics of Alzheimer’s disease. Rev Neurol 50(6):360–364 Schindler SE, Fagan AM (2015) Autosomal dominant Alzheimer disease: a unique resource to study CSF biomarker changes in preclinical AD. Front Neurol 6:142 Perry EK, Johnson M, Ekonomou A, Perry RH, Ballard C, Attems J (2012) Neurogenic abnormalities in Alzheimer’s disease differ between stages of neurogenesis and are partly related to cholinergic pathology. Neurobiol Dis 47(2):155–162 Martinez-Canabal A (2014) Reconsidering hippocampal neurogenesis in Alzheimer’s disease. Front Neurosci 8:147 Barage SH, Sonawane KD (2015) Amyloid cascade hypothesis: pathogenesis and therapeutic strategies in Alzheimer’s disease. Neuropeptides 52:1–18 Karran E, Mercken M, De Strooper B (2011) The amyloid cascade hypothesis for Alzheimer’s disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov 10(9):698–712 Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, Bjorsson S, Stefansson H, Sulem P et al (2012) A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline. Nature 488(7409):96–99 Tomiyama T, Nagata T, Shimada H, Teraoka R, Fukushima A, Kanemitsu H, Takuma H, Kuwano R et al (2008) A new amyloid beta variant favoring oligomerization in Alzheimer’s-type dementia. Ann Neurol 63(3):377–387 Maloney JA, Bainbridge T, Gustafson A, Zhang S, Kyauk R, Steiner P, Van der Brug M, Liu Y et al (2014) Molecular mechanisms of Alzheimer disease protection by the A673T allele of amyloid precursor protein. J Biol Chem 289(45):30990–31000 Kwok JB, Li QX, Hallupp M, Whyte S, Ames D, Beyreuther K, Masters CL, Schofield PR (2000) Novel Leu723Pro amyloid precursor protein mutation increases amyloid beta42(43) peptide levels and induces apoptosis. Ann Neurol 47(2):249–253 Nilsberth C, Westlind-Danielsson A, Eckman CB, Condron MM, Axelman K, Forsell C, Stenh C, Luthman J et al (2001) The ‘Arctic’ APP mutation (E693G) causes Alzheimer’s disease by enhanced Abetaprotofibril formation. Nat Neurosci 4(9):887–893 Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, Jones RW, Bullock R et al (2008) Long-term effects of Abeta42 immunisation in Alzheimer’s disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372(9634):216–223 Kim HY, Kim HV, Jo S, Lee CJ, Choi SY, Kim DJ, Kim Y (2015) EPPS rescues hippocampus-dependent cognitive deficits in APP/PS1 mice by disaggregation of amyloid-β oligomers and plaques. Nat Commun 6:8997 Green RC, Schneider LS, Amato DA, Beelen AP, Wilcock G, Swabb EA, Zavitz KH (2009) Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA 302(23):2557–2564 Liu B, Filippi S, Roy A, Roberts I (2015) Stem and progenitor cell dysfunction in human trisomies. EMBO Rep 16(1):44–62 Presson AP, Partyka G, Jensen KM, Devine OJ, Rasmussen SA, McCabe LL, McCabe ER (2013) Current estimate of Down syndrome population prevalence in the United States. J Pediatr 163(4):1163–1168 Wu J, Morris JK (2013) The population prevalence of Down’s syndrome in England and Wales in 2011. Eur J Hum Genet 21(9):1016–1019 Loane M, Morris JK, Addor MC, Arriola L, Budd J, Doray B, Garne E, Gatt M et al (2013) Twenty-year trends in the prevalence of Down syndrome and other trisomies in Europe: impact of maternal age and prenatal screening. Eur J Hum Genet 21(1):27–33 Stagni F, Giacomini A, Guidi S, Ciani E, Bartesagh R (2015) Timing of therapies for Down syndrome: the sooner, the better. Front Behav Neurosci 9:265 Ishihara K, Amano K, Takaki E, Shimohata A, Sago H, Epstein CJ, Yamakawa K (2010) Enlarged brain ventricles and impaired neurogenesis in the Ts1Cje and Ts2Cje mouse models of Down syndrome. Cereb Cortex 20(5):1131–1143 Haydar TF, Reeves RH (2012) Trisomy 21 and early brain development. Trends Neurosci 35(2):81–91 Dierssen M (2012) Down syndrome: the brain in trisomic mode. Nat Rev Neurosci 13(12):844–858 Choong XY, Tosh JL, Pulford LJ, Fisher EM (2015) Dissecting Alzheimer disease in Down syndrome using mouse models. Front Behav Neurosci 9:268 Schupf N, Sergievsky GH (2002) Genetic and host factors for dementia in Down’s syndrome. J Ment Sci 180:405–410